Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Squamous cell carcinoma presenting as anterior mediastinal mass with bilateral massive chylothorax in a young male.

Journal of postgraduate medicine·2026
Same author

Synergy between Paenibacillus lentimorbus and Pseudomonas putida mediates ecological benefit to chickpea by decrementing Fusarium oxysporum f. sp. ciceris.

Plant biology (Stuttgart, Germany)·2026
Same author

SymPET, a waveform digitizing "System on Chip" for ultra-high resolution TOF PET: design concept and preliminary studies.

IEEE Nuclear Science Symposium conference record. Nuclear Science Symposium·2025
Same author

Spaceflight alters host-gut microbiota interactions.

NPJ biofilms and microbiomes·2024
Same author

Response to "Comment on 'A spatially resolved optical method to measure thermal diffusivity'" [Rev. Sci. Instrum. 95, 047101 (2024)].

The Review of scientific instruments·2024
Same author

Observation of WWγ Production and Search for Hγ Production in Proton-Proton Collisions at sqrt[s]=13  TeV.

Physical review letters·2024

Related Experiment Video

Updated: Jun 8, 2026

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

Pentoxifylline in reactions in leprosy.

P C Singh1, S Mishra, M Mishra

  • 1Department of Skin and VD, VSS Medical College, Burla, Sambalpur-768017, India.

Indian Journal of Dermatology, Venereology and Leprology
|October 16, 2010
PubMed
Summary

Pentoxifylline effectively treated type 2 leprosy reactions, rapidly reducing erythema nodosum leprosum (ENL) lesions. However, it showed no benefit for type 1 leprosy reactions in this study.

Area of Science:

  • Infectious Diseases
  • Dermatology
  • Pharmacology

Background:

  • Leprosy reactions, particularly type 2 (erythema nodosum leprosum - ENL), pose significant treatment challenges.
  • Existing therapies for leprosy reactions can have limitations or side effects.
  • Pentoxifylline is an anti-inflammatory agent with potential therapeutic applications in various inflammatory conditions.

Purpose of the Study:

  • To evaluate the efficacy of pentoxifylline in managing different types of leprosy reactions.
  • To assess the treatment response in patients with type 2 reaction (ENL) and type 1 reaction.

Main Methods:

  • A study involving ten leprosy patients was conducted.
  • Eight patients had type 2 reaction (ENL), and two had type 1 reaction.

More Related Videos

Assay Development for High-Throughput Drug Screening Against Mycobacteria
07:50

Assay Development for High-Throughput Drug Screening Against Mycobacteria

Published on: October 25, 2024

Related Experiment Videos

Last Updated: Jun 8, 2026

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

Assay Development for High-Throughput Drug Screening Against Mycobacteria
07:50

Assay Development for High-Throughput Drug Screening Against Mycobacteria

Published on: October 25, 2024

  • Pentoxifylline was administered orally at a dosage of 400 mg three times daily.

    • Main Results:

    • Patients with type 2 reaction (ENL) showed a good clinical response within one week of pentoxifylline therapy.
    • Near complete regression of ENL lesions was observed in type 2 reaction patients within one month.
    • Patients experiencing type 1 reaction did not exhibit a positive response to pentoxifylline treatment.

    Conclusions:

    • Pentoxifylline demonstrates significant therapeutic potential for managing type 2 leprosy reactions (ENL).
    • The drug appears ineffective in treating type 1 leprosy reactions.
    • Further research into pentoxifylline's role in leprosy management is warranted, focusing on specific reaction types.